Thirteen percent of patients progressed to microalbuminuria during 7 years of follow-up. A high-risk subgroup consisting of 8% of the patient population was identified as having a risk of progression of 32% (Diabetologia 2010;53:254-62).
Dr. Maahs disclosed receiving research support from Merck and Eli Lilly.